title: Canakinumab for Childhood Sight-threatening Refractory Uveitis: A Case Series.
authors.affiliation: Rheumatology Unit, Azienda Ospedaliero Universitaria (AOU) Anna Meyer Children's Hospital; alice.brambilla02@ateneopv.it.
authors.forename: Alice
authors.initials: A
authors.lastname: Brambilla
authors.affiliation: Ophthalmology Unit, AOU Anna Meyer Children's Hospital;
authors.forename: Roberto
authors.initials: R
authors.lastname: Caputo
authors.affiliation: Rheumatology Unit, AOU Anna Meyer Children's Hospital;
authors.forename: Rolando
authors.initials: R
authors.lastname: Cimaz
authors.affiliation: Rheumatology Unit, AOU Anna Meyer Children's Hospital, Florence, Italy.
authors.forename: Gabriele
authors.initials: G
authors.lastname: Simonini
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002648:Child; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D012008:Recurrence; D018570:Risk Assessment; D012720:Severity of Illness Index; D041623:Tomography, Optical Coherence / Q000379:methods; D016896:Treatment Outcome; D014605:Uveitis / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D014786:Vision Disorders / Q000517:prevention & control*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C541220:canakinumab; D000069285:Infliximab; D000068879:Adalimumab; D008727:Methotrexate